BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen W, Ma T, Zhang J, Zhang X, Chen W, Shen Y, Bai X, Liang T. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. HPB (Oxford) 2020;22:795-808. [PMID: 31980307 DOI: 10.1016/j.hpb.2019.12.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Ye TW, Wang DD, Lu WF, Xie YM, Xu FQ, Fu TW, Zhang KJ, Liu SY, Xie GL, Cheng J, Jiang K, Xiao ZQ, Yao WF, Shen GL, Liu JW, Huang DS, Zhang CW, Liang L. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy. Expert Rev Gastroenterol Hepatol 2023;:1-9. [PMID: 36939280 DOI: 10.1080/17474124.2023.2192479] [Reference Citation Analysis]
2 Luo L, Shan R, Cui L, Wu Z, Qian J, Tu S, Zhang W, Xiong Y, Lin W, Tang H, Zhang Y, Zhu J, Huang Z, Li Z, Mao S, Li H, Hu Z, Peng P, He K, Li Y, Liu L, Shen W, He Y. Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort. United European Gastroenterol J 2023;11:228-41. [PMID: 36905230 DOI: 10.1002/ueg2.12365] [Reference Citation Analysis]
3 Zhou L, Zhang M, Chen S. Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis. Ann Hepatol 2023;28:100890. [PMID: 36574929 DOI: 10.1016/j.aohep.2022.100890] [Reference Citation Analysis]
4 Xu JX, Qin SL, Wei HW, Chen YY, Peng YC, Qi LN. Down-regulation of ALDOB during metabolic reprogramming mediates malignant behavior in hepatocellular carcinoma and insensitivity to postoperative adjuvant transarterial chemoembolization. Clin Sci (Lond) 2023;137:303-16. [PMID: 36749124 DOI: 10.1042/CS20220661] [Reference Citation Analysis]
5 Yang J, Jiang S, Chen Y, Zhang J, Deng Y. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence. Curr Oncol 2023;30:1708-19. [PMID: 36826093 DOI: 10.3390/curroncol30020132] [Reference Citation Analysis]
6 Li J, Yang F, Li J, Huang ZY, Cheng Q, Zhang EL. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World J Gastrointest Surg 2023; 15(1): 19-31 [DOI: 10.4240/wjgs.v15.i1.19] [Reference Citation Analysis]
7 Criss CR, Makary MS. Salvage locoregional therapies for recurrent hepatocellular carcinoma. World J Gastroenterol 2023; 29(3): 413-424 [PMID: 36688022 DOI: 10.3748/wjg.v29.i3.413] [Reference Citation Analysis]
8 Feng GY, Shi ZR, Zhao YF, Chen K, Tao J, Wei XF, Cheng Y. Therapeutic effect of postoperative adjuvant transcatheter arterial chemoembolization based on the neutrophil-to-lymphocyte ratio. Front Surg 2022;9:1072451. [PMID: 36684128 DOI: 10.3389/fsurg.2022.1072451] [Reference Citation Analysis]
9 Mo A, Zhang Q, Xia F, Huang Z, Peng S, Cao W, Mei H, Ren L, Su Y, Gao H, Chen W. Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): Multicenter retrospective study. Cancer Medicine 2022. [DOI: 10.1002/cam4.5529] [Reference Citation Analysis]
10 Zeng JS, Zeng JX, Huang Y, Liu JF, Zeng JH. The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00183-7. [PMID: 35934610 DOI: 10.1016/j.hbpd.2022.07.007] [Reference Citation Analysis]
11 Peng Y, He P, Gao X, Liu G, Cheng H. A Superstable Homogeneous Lipiodol-Nanoformulation to Overcome the Dilemma of Interventional Embolization Chemotherapy. Front Bioeng Biotechnol 2022;10:952194. [DOI: 10.3389/fbioe.2022.952194] [Reference Citation Analysis]
12 Li W, Liu J, Zhang D, Gu L, Zhao H. The Prognostic Significance and Potential Mechanism of Ferroptosis-Related Genes in Hepatocellular Carcinoma. Front Genet 2022;13:844624. [PMID: 35559035 DOI: 10.3389/fgene.2022.844624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Xu JX, Xing WT, Peng YC, Chen YY, Qi LN. Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index. Future Oncol 2022. [PMID: 35266821 DOI: 10.2217/fon-2021-1443] [Reference Citation Analysis]
15 Ke Q, Wang L, Wu W, Huang X, Li L, Liu J, Guo W. Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma. Front Oncol 2021;11:720079. [PMID: 35004268 DOI: 10.3389/fonc.2021.720079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34788184 DOI: 10.1080/13543784.2022.2008355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, Wang XW, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology 2021;73:1381-98. [PMID: 32609900 DOI: 10.1002/hep.31448] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
20 Zhao YF, Xiong X, Chen K, Tang W, Yang X, Shi ZR. Evaluation of the Therapeutic Effect of Adjuvant Transcatheter Arterial Chemoembolization Based on Ki67 After Hepatocellular Carcinoma Surgery. Front Oncol 2021;11:605234. [PMID: 33718156 DOI: 10.3389/fonc.2021.605234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Fung AKY, Cheng NMY, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Lai PBS, Ng KKC. Single-center experience on actual mid-term (≥5 years) and long-term (≥10 years) survival outcome in patients with hepatocellular carcinoma after curative hepatectomy: A bimodal distribution. Medicine (Baltimore) 2020;99:e23358. [PMID: 33235106 DOI: 10.1097/MD.0000000000023358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Huang Q, Lin K, Wang L, Zeng J, Liu H, Ding Z, Zeng Y, Liu J. Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study. Cancer Manag Res 2020;12:9183-95. [PMID: 33061610 DOI: 10.2147/CMAR.S270467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Masior Ł, Grąt M. Exploring new pathways in the treatment of hepatocellular cancer. Ann Transl Med 2020;8:980. [PMID: 32953780 DOI: 10.21037/atm-20-3629] [Reference Citation Analysis]